Prognostic significance of p21 and p27 protein, apoptosis, clinical and histologic factors in rectal cancer without lymph node metastases

European Surgical Research

Volumn 34, Issue 6, 2002, Pages 389-396

  Schwandner, Oliver ^a   Bruch, H P ^b   Broll, R ^b  

^a UNIVERSITY OF LÜBECK   (Germany)

^b NONE

Author keywords

Apoptosis; p21; p27; Prognosis; Rectal cancer

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P21; PROTEIN P27;

AGED; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL CYCLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NICK END LABELING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECORDING; RECTUM CARCINOMA; SAMPLE;

APOPTOSIS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IN SITU NICK-END LABELING; LYMPH NODES; LYMPHATIC METASTASIS; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECTAL NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0036968136     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065710     Document Type: Article

References (36)

1. Harper JW, Adami GR, Wie N, Keyomarsi K, Elledge SJ: The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
2. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995;9:1149-1163.
3. Xiong Y, Hannon GJ, Zang H, Casso D, Kobayashi R, Beach D: p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
4. Steeg PS, Abrams JS: Cancer prognostics: Past, present and p27. Nat Med 1997;3:152-154.
5. Katayose Y, Kim M, Amol NS, Rakkar ZL, Kenneth H, Prem S: Promiting apoptosis: A novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997;57:5441-5445.
6. Wang X, Gorospe M, Huang Y, Holbrook N: p27/kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997;15:2991-2997.
7. Bedi A, Pasricha PJ, Akhtar AJ, et al: Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811-1816.
8. Sobin LH, Wittekind C (UICC) (eds): TNM Classification of Malignant Tumours, ed 5. New York, Wiley-Liss, 1997.
9. Bruch HP, Schwandner O, Schiedeck THK, Roblick UJ: Actual standards and controversies on operative technique and lymph-node dissection in colorectal cancer. Langenbeck's Arch Surg 1999;384:167-175.
10. Bruch HP, Schwandner O, Sterk P, Schiedeck THK: Operative Therapie des Rektumkarzinoms. Aktuelle Entwicklungen unter besonderer Berücksichtigung sphinktererhaltender und laparoskopischer Eingriffe. Onkologe 2001;7:381-390.
11. Girlando S, Slomp P, Caffo O, Amichetti M, Tongi R, Dvornik G, Tomio L, Calligioni E, D'alla Palma P, Barbareschi M: p21 expression in colorectal carcinomas: A study on 103 cases with analysis of p53 gene mutation/expression and clinic-pathological correlations. Virchows Arch 1999;435:559-565.
12. Qiu H, Sirivongs P, Rothenberger M, Rothenberger DA, Garcia-Aguilar J: Molecular prognostic factors in rectal cancer treated by radiation and surgery. Dis Colon Rectum 2000;43:451-459.
13. Viale G, Pellegrini C, Mazzarol G, Maisonneuve P, Silverman ML, Bosair S: p21/WAF1/CIP1 expression in colorectal carcinoma correlate with advanced disease stage and p53 mutations. J Pathol 1999;187:302-307.
14. Langlois N, Lamb J, Eremin O, Heys SD: Apoptosis in colorectal carcinoma occurring in patients aged 45 years and under: Relationship to prognosis, mitosis, and immunohistochemical demonstration of p53, c-myc and bcl-2 protein products. J Pathol 1997;182:392-397.
15. Bruch HP, Schwandner O: Totale mesorektale Exzision beim Rektumkarzinom: Das Dissektionsprinzip ohne kontrollierte Daten. Viszeralchirurgie 2002;37:6-11.
16. Wexner SD, Rotholtz NA: Surgeon-influenced variables in resectional rectal cancer surgery. Dis Colon Rectum 2000;43:1606-1627.
17. Hermanek P: Imapct of surgeon's technique on outcome after treatment of rectal carcinoma. Dis Colon Rectum 1999;42:559-562.
18. Köckerling F, Reymond MA, Altendorf-Hofmann A, Dworak O, Hohenberger W: Influence of surgery on metachronous distant metastases and survival in rectal cancer. J Clin Oncol 1998;16:324-329.
19. Mulcahy HE, Toner M, Patchett SE, Daly L, O'Donoghue DP: Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death. Dis Colon Rectum 1997;40:326-331.
20. NIH consensus conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1450.
21. Günther K, Radkow T, Reymond MA, Pflüger R, Dimmler A, Hohenberger W, Papadopoulos TH: Angiogenese und Dichte dendritischer Zellen korrelieren nicht mit der metachronen Fernmetastasierung beim kurativ operierten Rektumkarzinom. Chirurg 2001;72:1144-1153.
22. Hermanek P: Prognostic factor research in oncology. J Clin Epidemiol 1999;52:371-374.
23. Galandiuk S, Wieand HS, Moertel CG, et al: Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27-32.
24. Michelassi F, Vannucci L, Ayala JJ, Chappel R, Goldberg R, Block GE: Local recurrence after curative resection of colorectal adenocarcinoma. Surgery 1990;108:787-792.
25. Konn M, Morita T, Hada R, et al: Survival and recurrence after low anterior resection and ab-dominoperineal resection for rectal cancer. The results of a long-term study with a review of the literature. Surg Today 1993;23:21-30.
26. Schwandner O, Bruch HP, Broll R: p21, p27, cyclin D1, and p53 in rectal cancer: Immunohistology with prognostic significance? Int J Colorectal Dis 2002;17:11-19.
27. Schwandner O, Schiedeck THK, Bruch HP, Duchrow M, Windhoevel U, Broll R: p53 and Bcl-2 as significant predictors of recurrence and survival in rectal cancer. Eur J Cancer 2000;36:348-356.
28. Fu CG, Tominaga O, Nagawa H, Nita ME, Masaki T, Ishimaru G, Higuchi Y, Tsuruo T, Muto T: Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 1998;41:68-74.
29. Tenjo T, Toyoda M, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Ohtani M, Nohara T, Kawasaki H, Tanigawa N: Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 2000;58:45-51.
30. Burdy G, Panis Y, Alves A, Nemeth J, Lavergne-Slove A, Valleur P: Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001;44:1682-1688.
31. Zirbes TK, Baldus SE, Moenig SP, Nolden S, Kunze D, Shafizadeh ST, Schneider PM, Thiele J, Hoelscher AH, Dienes HP: Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int J Cancer 2000;89:14-18.
32. Bukholm IK, Nesland JM: Protein expression of p53, p21 (WAF1/CIP1), bcl-2, Bax, cyclin D1 and pRb in human colon carcinomas. Virchows Arch 2000;436:224-228.
33. Palmquist R, Stenling R, Oberg A, Landberg G: Prognostic significance of p27(Kip1) expression in colorectal cancer: A clinico-pathological characterization. J Pathol 1999;188:18-23.
34. McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FY, Loane JF, Murray GI, McLeod HL: Expression of cell cycle control proteins in primary colorectal tumors does not always predict expression in lymph node metastases. Clin Cancer Res 2000;6:1113-1118.
35. Esposito G, Pucciarelli S, Alaggio R, Giacomelli L, Marchiori E, Iaderosa GA, Friso ML, Toppan P, Chieco-Bianchi L, Lise M: p27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer. Ann Surg Oncol 2001;8:311-318.
36. Marijnen CA, Kapiteijn E, Nagtegaal ID, Mulder-Stapel AA, van de Velde CJ, Schrier PI, Peltenburg LT, van Krieken JH: p53 expression in human rectal tissue after radiotherapy: Upregulation in normal mucosa versus functional loss in rectal carcinomas. Int J Radiat Oncol Biol Phys 2002;52:720-728.